Lung Cancer
Small Cell Lung Cancer (SCLC)
• Accounts for ~15% of cases
• Central, arises from neuroendocrine Kulchitsky cells
• Highly aggressive, rapid doubling time, early widespread metastases:
o Brain (common cause of paraneoplastic encephalopathy)
o Liver
o Bone
o Adrenal glands
• Paraneoplastic syndromes:
o SIADH → hyponatraemia (euvolaemic)
o Ectopic ACTH → Cushing's syndrome
o Lambert-Eaton myasthenic syndrome → proximal muscle weakness improves with use
• Treatment: usually chemotherapy ± radiotherapy, surgery rare due to early spread
Non-Small Cell Lung Cancer (NSCLC)
• ~85% of lung cancers; subtypes:
Squamous cell carcinoma
• Central, often cavitating
• Strong smoking association
• Produces PTHrP → hypercalcaemia
• Can cause obstructive pneumonia
Adenocarcinoma
• Peripheral, subpleural
• Most common type in non-smokers and women
• May present as solitary pulmonary nodule
• May arise in scarred lung ("scar carcinoma")
Large cell carcinoma
• Poorly differentiated, can be central or peripheral
• Rapid growth, early metastasis
• Associated with poor prognosis
Diagnostic Pathway
• Initial: CXR (e.g., hilar mass, effusion, collapse)
• CT thorax and upper abdomen: staging, operability
• PET-CT: identifies occult metastases
• Tissue diagnosis:
o Bronchoscopy ± endobronchial ultrasound (EBUS) for central lesions/lymph nodes
o CT-guided percutaneous biopsy for peripheral lesions
Colorectal Cancer
Right-sided (proximal)
• Features:
o Iron deficiency anaemia (occult bleeding)
o Weight loss
o Mass in right iliac fossa
• More common in Lynch syndrome (HNPCC)
Left-sided (distal)
• Features:
o Change in bowel habit (often alternating diarrhoea and constipation)
o Obstructive symptoms (colicky pain, distension)
o Fresh rectal bleeding
• Apple-core lesion on barium enema (historical)
Rectal
• Features:
o Tenesmus (feeling of incomplete emptying)
o Urgency
o Rectal bleeding
• Digital rectal exam important
Molecular subtypes
• Microsatellite instability (MSI): seen in Lynch syndrome
• Chromosomal instability (APC pathway): sporadic majority
Breast Cancer
Types
• Invasive ductal carcinoma (~80%): most common type, firm ("stellate" on imaging)
• Invasive lobular carcinoma:
o Tends to be bilateral and multicentric
o "Single-file" cells histologically
Molecular subtypes
• Triple negative (ER-, PR-, HER2-):
o More aggressive, higher risk of early recurrence
o Common in BRCA1 mutation carriers
• HER2-positive:
o Targeted therapy: trastuzumab (Herceptin)
o Requires cardiac monitoring (risk of cardiomyopathy)
Risk factors
• Nulliparity
• Late first pregnancy
• Early menarche, late menopause
• Hormone replacement therapy
Screening
• Mammography screening (UK): age 50–70, every 3 years
Prostate Cancer
Features
• Age-related, very common in elderly men
• Arises from peripheral zone → often asymptomatic early
• PSA:
o Typically >4 ng/mL (age-adjusted cut-offs used)
o Can also rise with prostatitis and BPH
• Metastases:
o Bone metastases → osteoblastic/sclerotic lesions
o Features: back pain, pathological fractures, raised ALP, hypercalcaemia (rare)
Diagnosis
• Digital rectal exam: hard, irregular prostate
• Transrectal ultrasound-guided biopsy for histology
• MRI for staging (locoregional spread)
Ovarian Cancer
Features
• Often late presentation with vague symptoms:
o Abdominal distension ("bloating")
o Early satiety
o Pelvic/abdominal pain
o Urinary urgency
• CA-125:
o Elevated in ~80%, but non-specific
o Also rises with benign conditions (e.g., endometriosis, menstruation, liver disease)
Types
• High-grade serous carcinoma: most common and aggressive
• Mucinous, endometrioid, clear cell: less common
Risk factors
• BRCA1/2 mutations (lifetime risk up to 40% in BRCA1)
• Nulliparity, infertility
• Early menarche, late menopause
Protective factors
• Pregnancy, breastfeeding
• Oral contraceptive pill
Extra Revision Pearls
• Lynch syndrome: think right-sided colon cancer and associated endometrial cancer
• BRCA1: more often triple negative breast cancer, higher ovarian risk
• Prostate cancer metastases: sclerotic vs lytic bone metastases (breast can be mixed, myeloma purely lytic)
• CA-125: not a screening tool but useful in monitoring treatment response